Similarly, given the recent demonstration that METTL3 catalytic inhibition sensitizes tumor cells to genotoxic agents, such as the PARPi olaparib [48], METTL3 inhibitors could be utilized to enhance the efficacy of these agents to eliminate LSCs and to induce synthetic lethality in CML patients that do not respond to standard TKI-based therapy. The gene discussed is METTL3; the disease is neoplasm.